CN103189504B - 减少炎性反应的具有减少的脂磷壁酸的重组乳杆菌 - Google Patents

减少炎性反应的具有减少的脂磷壁酸的重组乳杆菌 Download PDF

Info

Publication number
CN103189504B
CN103189504B CN201180039874.2A CN201180039874A CN103189504B CN 103189504 B CN103189504 B CN 103189504B CN 201180039874 A CN201180039874 A CN 201180039874A CN 103189504 B CN103189504 B CN 103189504B
Authority
CN
China
Prior art keywords
bacterium
subject
purposes
lta
lactobacillus acidophilus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180039874.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103189504A (zh
Inventor
T.R.克莱恩哈默
E.普菲勒
M.莫哈马扎德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NORTHWEST UNIVERSITY
North Carolina State University
Original Assignee
NORTHWEST UNIVERSITY
North Carolina State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NORTHWEST UNIVERSITY, North Carolina State University filed Critical NORTHWEST UNIVERSITY
Priority to CN201710266701.3A priority Critical patent/CN107325979B/zh
Publication of CN103189504A publication Critical patent/CN103189504A/zh
Application granted granted Critical
Publication of CN103189504B publication Critical patent/CN103189504B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1288—Transferases for other substituted phosphate groups (2.7.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/08—Transferases for other substituted phosphate groups (2.7.8)
    • C12Y207/0802—Phosphatidylglycerol--membrane-oligosaccharide glycerophosphotransferase (2.7.8.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/23—Lactobacillus acidophilus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201180039874.2A 2010-06-18 2011-06-16 减少炎性反应的具有减少的脂磷壁酸的重组乳杆菌 Expired - Fee Related CN103189504B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710266701.3A CN107325979B (zh) 2010-06-18 2011-06-16 减少炎性反应的具有减少的脂磷壁酸的重组乳杆菌

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35616510P 2010-06-18 2010-06-18
US61/356165 2010-06-18
US61/356,165 2010-06-18
US201161433598P 2011-01-18 2011-01-18
US61/433598 2011-01-18
US61/433,598 2011-01-18
PCT/US2011/040674 WO2011159880A1 (en) 2010-06-18 2011-06-16 Recombinant lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710266701.3A Division CN107325979B (zh) 2010-06-18 2011-06-16 减少炎性反应的具有减少的脂磷壁酸的重组乳杆菌

Publications (2)

Publication Number Publication Date
CN103189504A CN103189504A (zh) 2013-07-03
CN103189504B true CN103189504B (zh) 2017-05-24

Family

ID=44529869

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180039874.2A Expired - Fee Related CN103189504B (zh) 2010-06-18 2011-06-16 减少炎性反应的具有减少的脂磷壁酸的重组乳杆菌
CN201710266701.3A Active CN107325979B (zh) 2010-06-18 2011-06-16 减少炎性反应的具有减少的脂磷壁酸的重组乳杆菌

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710266701.3A Active CN107325979B (zh) 2010-06-18 2011-06-16 减少炎性反应的具有减少的脂磷壁酸的重组乳杆菌

Country Status (5)

Country Link
US (2) US9340792B2 (enExample)
EP (1) EP2582800B1 (enExample)
JP (3) JP6154320B2 (enExample)
CN (2) CN103189504B (enExample)
WO (1) WO2011159880A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2793916A1 (en) * 2011-12-20 2014-10-29 North Carolina State University Methods to reduce polyposis and colorectal cancer
WO2013188529A1 (en) 2012-06-15 2013-12-19 Temple University Of The Commonwealth System Of Higher Education Use of isolated bacterial amyloids for treatment of inflammatory disorders or diseases of the epithelium
JP2015087167A (ja) * 2013-10-29 2015-05-07 キヤノン株式会社 画像処理方法、画像処理システム
WO2016124239A1 (en) * 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction
GB201514302D0 (en) * 2015-07-16 2015-09-23 Dupont Nutrition Biosci Aps Lactobacilli for treating cardiac dysfunction
CN109804432B (zh) 2016-04-15 2023-07-14 武田药品工业株式会社 提供药代动力学药物给药方案的方法和设备
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
CN116655731A (zh) * 2023-06-30 2023-08-29 吉林大学 一条具有辅助治疗溃疡性结肠炎作用的蛋清肽序列及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6159447A (en) * 1997-10-16 2000-12-12 Pharmacal Biotechnologies, Llc Compositions for controlling bacterial colonization

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Lipoteichoic acids on Lactobacillus plantarum cell surfaces correlate with induction of interleukin-12p40 production;YOSHITAKA HIROSE et al.;《MICROBIOLOGY AND IMMUNOLOGY》;20100310;第54卷(第3期);摘要、图5 *
Synthesis of glycerol phosphate lipoteichoic acid in Staphylococcus aureus;GRUNDLING ANGELIKA et al.;《PNAS》;20070515;第104卷(第20期);第8478页左栏第1段、第8479页左栏第1段-第8480页右栏第1段 *
乳杆菌对肠上皮样细胞HT-29黏附的研究;王斌 等;《中华微生物学和免疫学杂志》;20041130;第24卷(第11期);858 *
乳杆菌粘附机制的研究进展;王斌;《国际检验医学杂志》;20060328;第27卷(第03期);224-226 *

Also Published As

Publication number Publication date
EP2582800B1 (en) 2016-11-09
CN103189504A (zh) 2013-07-03
JP6154320B2 (ja) 2017-07-05
JP2017153485A (ja) 2017-09-07
CN107325979B (zh) 2023-01-24
US20130224153A1 (en) 2013-08-29
JP6606124B2 (ja) 2019-11-13
JP2019208513A (ja) 2019-12-12
JP2013537402A (ja) 2013-10-03
EP2582800A1 (en) 2013-04-24
WO2011159880A1 (en) 2011-12-22
US9340792B2 (en) 2016-05-17
US20160324905A1 (en) 2016-11-10
US9980992B2 (en) 2018-05-29
CN107325979A (zh) 2017-11-07

Similar Documents

Publication Publication Date Title
JP6606124B2 (ja) 炎症応答を減少させるための、リポテイコ酸が減少した組み換えラクトバチルス
KR102469701B1 (ko) 점막부착성 미생물
CN107109348B (zh) 益生菌青春双歧杆菌菌株
CN112534043A (zh) 副干酪乳杆菌菌株及其用途
JP6770269B2 (ja) 経口腫瘍ワクチン
JP6669703B2 (ja) 改変されたグラム陽性菌及びその使用
CN102341499B (zh) 用于制备hpv疫苗和由其转化的重组乳酸菌的稳定组成型高表达载体
JP2020505036A (ja) 抗原に対する防御免疫の誘導
CN101155911B (zh) 5-氟尿嘧啶耐受菌及其制备方法
JP2014526266A (ja) 改変されたグラム陽性菌及びその使用
CN114761563B (zh) 诱导型质粒自毁辅助重组
WO2013096297A1 (en) Methods to reduce polyposis and colorectal cancer
JP6810877B2 (ja) 経口腫瘍ワクチンと免疫抑制阻害剤との併用によるがん治療
JP5871617B2 (ja) 偏性嫌気性に変異化された乳酸菌およびその作製方法ならびに偏性嫌気性乳酸菌で機能する発現ベクター
JP2007530034A (ja) 新規のマンノース特異的アドヘシンとその使用
HK40040941A (en) Lactobacillus paracasei strain and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170524

Termination date: 20180616